Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Autores: Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, et al.
Revista
N Engl J Med
Año
2023
Citas
450
Type
Clinical Trial
Subject
Human
Condition
Obesity / Type 2 Diabetes
TL;DR
Phase 2 trial of retatrutide (GLP-1/GIP/glucagon triple agonist) in adults with obesity demonstrated dose-dependent weight loss and acceptable safety profile.
Ver Artículo
DOI: 10.1056/NEJMoa2301972
Abstract
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known.. We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the.